Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03215940 · ClinicalTrials.gov registry record · Early Phase 1
Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)
A Early Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 53
- Enrollment target
NCT03215940 is a Early Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 53 participants.
The verdict
NCT03215940, a Early Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a study comparing the effects of Delta-9-Tetrahydrocannabinol (THC) versus Cannabidiol (CBD) versus a placebo on chronic non-cancer pain.
Interventions
- DRUG Cannabidiol
- DRUG Placebos
- DRUG Delta-9-Tetrahydrocannabinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2024-12-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03215940
The ClinicalTrials.gov registry entry for NCT03215940 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cannabidiol is the first listed.
NCT03215940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03215940 about?
NCT03215940 is a clinical study titled "Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)". This is a study comparing the effects of Delta-9-Tetrahydrocannabinol (THC) versus Cannabidiol (CBD) versus a placebo on chronic non-cancer pain.
What is the current status of trial NCT03215940?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 53 participants. The study started on 2018-02-01. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT03215940?
The interventions under investigation include: Cannabidiol (DRUG), Placebos (DRUG), Delta-9-Tetrahydrocannabinol (DRUG).
Who is sponsoring clinical trial NCT03215940?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.